Status:

COMPLETED

Epidural-inhalational Versus Epidural-intravenous Anaesthesia on Anti-tumor Immunity in Patients With Cancer Colon

Lead Sponsor:

South Egypt Cancer Institute

Conditions:

Immunity Factors in Cancer Colon Patients

Eligibility:

All Genders

20-70 years

Phase:

NA

Brief Summary

Surgery is the primary treatment for colon cancer. However, the rate of recurrence or metastasis in colon cancer can be as high as 30%, even in stages 1 and 2 . Most colon cancer-related deaths are ca...

Eligibility Criteria

Inclusion

  • Age 20-70 yrs.
  • ASA class I and II
  • Elective open surgery for non-metastatic cancer colon stage I,II

Exclusion

  • Patient refusal
  • Known allergy to the study medications
  • Patients with compromised immune function ( associated blood diseases, immunosuppressive drugs, chemotherapeutic agents, corticosteroids)
  • Contraindications to epidural insertion e.g. infection at insertion site and coagulopathy

Key Trial Info

Start Date :

April 15 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2020

Estimated Enrollment :

48 Patients enrolled

Trial Details

Trial ID

NCT04518579

Start Date

April 15 2018

End Date

August 1 2020

Last Update

August 21 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

South Egypt Cancer Institute

Asyut, Egypt, 71511

Epidural-inhalational Versus Epidural-intravenous Anaesthesia on Anti-tumor Immunity in Patients With Cancer Colon | DecenTrialz